Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...

We are delighted to welcome Stephen to TScan at this stage of growth for the Company,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “His robust commercial leadership experience includes over ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences' Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy after just one earlier systemic therapy, moving the approach up the treatment pathway. The US ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor ...

A subsidiary of Gilead Sciences, Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered ...

Parking is $5. 303 BerryFest Place, Plant City. flstrawberryfestival.com. Sand & Kites & Coastal Delights: After a challenging few months of recovery from Hurricanes Helene and Milton, Treasure ...